Company: RENEF
Filing Date: 2025-10-20
Form Type: DEF 14A
Source: 0001104659-25-100857
Chunk: 17

Company: Cartesian Growth Corp II
Filing Date: 2025-10-20
Form: DEF 14A
Chunk 17
---
How do the Company insiders intend to vote their shares?

The Sponsor and other initial
shareholders and their permitted transferees (collectively, the “Initial Shareholders”) collectively have the right to vote
approximately 44.2% of the Company’s issued and outstanding Ordinary Shares and are expected to vote all of their shares in favor
of each proposal to be voted upon by our shareholders.

Subject to applicable securities
laws (including with respect to material nonpublic information), the Sponsor, the Company’s directors, officers, advisors or any
of their respective affiliates may (i) purchase public shares from institutional and other investors (including those who vote, or indicate
an intention to vote, against any of the proposals presented at the Extraordinary General Meeting, or elect to redeem, or indicate an
intention to redeem, public shares), (ii) enter into transactions with such investors and others to provide them with incentives to not
redeem their public shares, or (iii) execute agreements to purchase such public shares from such investors or enter into non-redemption
agreements in the future. In the event that the Sponsor, the Company’s directors, officers, advisors or any of their respective
affiliates purchase public shares in situations in which the tender offer rules restrictions on purchases would apply, they (a) would
purchase the public shares at a price no higher than the price offered through the Company’s redemption process (i.e., approximately
$12.24 per share, based on the amounts held in the Trust Account as of October 17, 2025); (b) would represent in writing that such public shares will not be voted in favor of approving the Extension; and (c) would
waive in writing any redemption rights with respect to the public shares so purchased.

<div align='center'>4</div>

To the extent any such purchases
by the Sponsor, the Company’s directors, officers, advisors or any of their respective affiliates are made in situations in which
the tender offer rules restrictions on purchases apply, the Company will disclose in a Current Report on Form 8-K prior to the Extraordinary
General Meeting the following: (i) the number of public shares purchased outside of the redemption offer, along with the purchase price(s)
for such public shares; (ii) the purpose of any such purchases; (iii) the impact, if any, of the purchases on the likelihood that the
Extension will be approved; (iv) the identities of the securityholders who sold to the Sponsor